Tumour assessment in advanced melanoma: Value of FDG-PET/CT in patients with elevated serum S-100B

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1366-1375

  Strobel, Klaus ^a   Skalsky, Jeannine ^b   Kalff, Victor ^a,c   Baumann, Katrin ^b   Seifert, Burkhardt ^d   Joller Jemelka, Helen ^a   Dummer, Reinhard ^b   Steinert, Hans C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Melanoma; Metastases; PET CT; S 100B

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN S100B; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

EID: 34548184430     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0403-8     Document Type: Article

References (36)

1. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153-67.
2. 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-87.
3. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-7.
4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
5. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998;138:426-30.
6. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100-a marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208-12.
7. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-71.
8. Hansson LO, von Schoultz E, Djureen E, Hansson J, Nilsson B, Ringborg U. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res 1997;17:3071-3.
9. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997;75:1373-6.
10. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997;137:381-5.
11. Andres R, Mayordomo JI, Zaballos P, Rodino J, Isla D, Escudero P, et al. Prognostic value of serum S-100B in malignant melanoma. Tumori 2004;90:607-10.
12. Domingo-Domenech J, Molina R, Castel T, Montagut C, Puig S, Conill C, et al. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon-comparison with tyrosinase rt-PCR. Oncology 2005;68:341-9.
13. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
14. 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001;8:779-86.
15. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8, discussion 38-9.
16. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98.
17. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:39-44.
18. 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
19. Wagner JD, Schauwecker D, Davidson D, Coleman JJ 3rd, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-15.
20. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-11, discussion 303-11.
21. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-8.
22. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-42.
23. 18F-FDG PET and clinical data. Nuklearmedizin 2002;41:143-7.
24. Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001;18:491-8.
25. Spinella PC, Dominguez T, Drott HR, Huh J, McCormick L, Rajendra A, et al. S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury. Crit Care Med 2003;31:939-45.
26. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 2002;23:39-44.
27. Banfalvi T, Gergye M, Beczassy E, Gilde K, Otto S. Role of S100B protein in neoplasms and other diseases. Magy Onkol 2004;48:71-4.
28. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181-7.
29. Sze G, Shin J, Krol G, Johnson C, Liu D, Deck MD. Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology 1988;168:187-94.
30. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
31. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85.
32. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-59.
33. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001;19:824-31.
34. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000;143:269-74.
35. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005;20:34-42.
36. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-71.